Syneron and Viora Announce Settlement Agreement of Business and Patent Litigations

YOKNEAM, Israel, June 4, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, and Viora Ltd. and Viora Inc., a global manufacturer and distributor of medical aesthetic devices ("Viora"), announced today that they have entered into an agreement  to settle Syneron's patent infringement law suit against Viora in the United States and a business litigation in Israel. As part of the settlement, Viora acknowledged that its Reaction product infringes Syneron's U.S. patent No. 6,662,054, and acknowledged the validity of the patent. Viora further agreed that for the next 12 years, it will pay Syneron royalties of 7.5% to 15%, depending on the number of systems sold by Viora on all U.S. sales of products that apply vacuum together with radio frequency energy for body contouring, cellulite reduction, skin tightening and circumferential reduction.

Amit Meridor, Chief Executive Officer of Syneron Medical, said, "We are pleased to reach this settlement that supports the  validity of one of our key VelaShape patents and ends the legal activity related to this matter. As a leading innovator in the aesthetic medical device market, we have developed numerous patented technologies and we intend to vigorously defend our intellectual property."

Eliran Almog, Chief Executive Officer of Viora Inc., said, "Viora is happy to achieve this settlement with Syneron. The end of this dispute will enable us to provide uninterrupted, access to the Reaction™ technology, in addition to renewing our focus on our customers, ensuring continued customer and patient satisfaction."

About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

About Viora
Viora is a market leader in the development of technologically advanced medical aesthetic systems for physicians and aesthetic clinicians worldwide. Dedicated to the research and development of safe and effective aesthetic solutions, Viora provides the highest standard of professional grade solutions. For more information on Viora, visit www.vioramed.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Logo - http://photos.prnewswire.com/prnh/20120528/535447

SOURCE Syneron Medical Ltd.

Related Links

http://www.syneron-candela.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED